Apixaban: an Oral Direct Factor-Xa Inhibitor Authors
First Online: 17 February 2012 Received: 23 December 2011 DOI:
Cite this article as: Jiménez, D., Yusen, R.D. & Ramacciotti, E. Adv Therapy (2012) 29: 187. doi:10.1007/s12325-012-0003-2
Apixaban is a highly selective, reversible, direct factor Xa inhibitor that inhibits both free factor Xa and prothrombinase activity, and clot-bound factor Xa activity. A predictable pharmacokinetic profile, multiple pathways of elimination, an improved bleeding profile relative to warfarin with a lack of other significant adverse events, and no need for routine anticoagulation monitoring make apixaban appealing. Apixaban is currently approved for venous thromboembolism (VTE) prophylaxis in total hip replacement and total knee replacement in Europe, Brazil, Australia, and New Zealand, and has been pre-approved in Indonesia and the Philippines. Completed phase 3 trials suggest that apixaban has promise as an alternative to aspirin and warfarin for prevention of stroke and systemic embolism in patients with atrial fibrillation. Results of a large phase 3 trial were the first to show a survival benefit for this new class of oral anticoagulants in patients with atrial fibrillation. In patients with acute coronary syndrome, apixaban added to dual antiplatelet therapy with aspirin and clopidogrel resulted in unacceptably high rates of major bleeding. In medically ill patients, an extended course of thromboprophylaxis with apixaban was not superior to a shorter course with enoxaparin, and was associated with significantly more major bleeding events than enoxaparin. Ongoing phase 3 trials will provide data regarding the efficacy and safety of apixaban for treatment of acute deep vein thrombosis and pulmonary embolism.
Acute coronary syndrome
Deep vein thrombosis
To view enhanced content go to
Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756–764.
Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107(suppl. 1):I22–I30.
Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133(suppl.): 141S–159S.
Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidencebased clinical practice guidelines. Chest. 2008;133(suppl.): 160S–198S.
Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8
Edition). Chest. 2008;133(suppl.): 381S–453S.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867.
Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095–1106.
Wittkowsky AK. Warfarin and other coumarin derivates: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med. 2003;3:221–230.
O’Reilly RA. Warfarin metabolism and drug-drug interactions. Adv Exp Med Biol. 1987;214:205–212.
Hirsh J, Guyatt G, Albers GW, Harrington R, Schunemann HJ. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8
Edition). Chest. 2008;133(suppl.): 110S–112S.
Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6:820–829.
Wong PC, Jiang X. Apixaban, a direct factor Xa inhibitor, inhibits tissue factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost. 2010;104:302–310.
Vakkalagadda B, Frost C, Wang J, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa [abstract]. J Clin Pharmacol. 2009;49:1124. Abstract 143.
Frost C, Yu Z, Nepal S, et al. Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation [abstract]. J Clin Pharmacol. 2008;48:1132.
Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37:74–81.
Song Y, Cui Y, Li T, et al. Apixaban pharmacokinetics and pharmacodynamics in healthy Chinese subjects [abstract]. J Clin Pharmacol. 2010;50:1062.
Yamahira N, Imai Y, Wastall P, et al. A placebocontrolled, ascending multiple-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of apixaban in healthy Japanese subjects (A637). Can J Clin Pharmacol. 2008;15:e420–e781.
Frost C, Yu Z, Moore K, et al. Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects. J Thromb Haemost. 2007;5(suppl.2):PxxxMxxx664.
Perzborn E, Tersteegen A, Harwardt M, Lange U. Different characteristics of direct factor Xa inhibitors: in vitro comparative studies of rivaroxaban and apixaban. Blood (ASH Annual Meeting Abstracts). 2009;114:4170.
He K, Luettgen JM, Zhang D, et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet. 2011;36:129–139.
Frost C, Yu Z, Shenker A, Nepal S. Food does not affect the pharmacokinetics of apixaban, an oral, factor Xa inhibitor. Can J Clin Pharmacol (WCCPT Meeting Abstracts). 2008;15:e469.
ELIQUIS prescribing information. Available at:
. Accessed Oct 5 2011.
Prom R, Spinler SA. The role of apixaban for venous and arterial thromboembolic disease. Ann Pharmacother. 2011;45:1262–1283.
Becker RC, Yang H, Barrett Y, et al. Chromogenic laboratory assays to measure the factor Xainhibiting properties of apixaban — an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis. 2011;32:183–187.
Huang J, Cao Y, Liao C, Wu L, Gao F. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb Haemost. 2010;105:245–253.
Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361:594–604.
Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375:807–815.
Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363:2487–2498.
Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167–2177.
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–694.
Botticelli Investigators, Writing Committee, Buller H, Deitchman D, Prins M, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis: The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6:1313–1318.
Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–817.
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877–2885.
Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699–708.
Chesebro JH, Knatterud G, Roberts R et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987;76:142–154.
Wallentin LC, Lopes RD, Hanna M, et al. ARISTOTLE: Efficacy and safety of apixaban compared to warfarin at different levels of INR control for stroke prevention in 18,202 patients with atrial fibrillation in the ARISTOTLE trial. ESC Congress Abstracts 2011. Available at:
. Accessed Oct 24 2011.
Wang L, Zhang D, Raghavan N, et al. Assessment of drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction. Drug Metab Dispos. 2010;38:448–458.
van Bladel ER, Agterof MJ, Frijling BD, et al. Out of hospital anticoagulant therapy in patients with acute pulmonary embolism is frequently practised but not perfect. Thromb Res. 2010;126:481–485.
Spirk D, Banyai M, Jacomella V, et al. Outpatient management of acute deep vein thrombosis: results from the OTIS_DVT registry. Thromb Res. 2011;127:406–410.
Aujesky D, Obrosky DS, Stone RA, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005;172:1041–1046.
Jiménez D, Aujesky D, Moores L, et al. Simplification of the pulmonary embolism severity index for prognosticating patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170:1383–1389.
Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, openlabel, randomised, non-inferiority trial. Lancet. 2011;378:41–48
PubMed CrossRef Copyright information
© Springer Healthcare 2012